Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL-2.70%NVDA+3.63%AMZN+1.69%SPCX-7.69%TSM-9.36%AVGO-12.19%META+1.21%TSLA+1.46%LLY-0.30%WMT+1.52%JPM-2.98%BRK-B-0.36%V-0.09%SKHY-13.11%AMD-13.25%MU+2.48%XOM+0.67%JNJ+1.25%MA-0.06%ABBV+0.94%ASMLa+0.68%COST+0.76%1398.HK+0.25%KO+0.94%CVX+0.91%0700.HK-1.26%PG+0.91%CSCO-4.29%0939.HK0.00%HD+0.72%3988.HK-1.13%BAC-3.15%1816.HK+3.45%GE-2.87%0857.HK-0.49%ORCL-8.48%UNH+2.85%1288.HK-0.45%PM-1.26%0005.HK-3.08%NVS-0.50%HSBA.L+0.29%INTC-7.97%AZN-0.60%MS-5.32%RTX-1.58%ORp+0.16%TMO-2.79%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.08%ETHUSD+71.01%USDTUSD+0.13%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.23%ZECUSDT+2.21%XMRUSDT-0.09%DOGEUSD+69.80%LINKUSD+2.45%XLMUSD-0.44%BCHUSDT-0.15%LTCUSD+68.40%UNIUSD-0.57%TONUSD+79.92%SUIUSD+1.82%HBARUSDT-0.07%TAOUSDT+2.85%AAVEUSD+1.52%ONDOUSDT+1.26%DOTUSDT+1.46%ICPUSDT+2.21%WLDUSDT+2.88%ARBUSDT+2.88%ATOMUSDT+1.90%INJUSDT+5.70%STXUSDT+4.18%PYTHUSDT+3.71%TIAUSDT+3.05%FETUSDT-0.13%SEIUSDT+0.59%JUPUSDT+2.33%GRTUSDT+0.86%OPUSDT+2.97%IOTAUSDT+2.14%POLUSDT+0.15%WIFUSDT+2.36%AXSUSDT+0.17%EOSUSDT+0.99%IMXUSDT+0.09%FARTCOINUSDT+1.61%GALAUSDT+3.50%DYDXUSDT+0.84%ORDIUSDT+2.72%NOTUSDT+1.19%RONINUSDT+1.91%AAPL+0.69%MSFT+0.96%GOOGL-2.70%NVDA+3.63%AMZN+1.69%SPCX-7.69%TSM-9.36%AVGO-12.19%META+1.21%TSLA+1.46%LLY-0.30%WMT+1.52%JPM-2.98%BRK-B-0.36%V-0.09%SKHY-13.11%AMD-13.25%MU+2.48%XOM+0.67%JNJ+1.25%MA-0.06%ABBV+0.94%ASMLa+0.68%COST+0.76%1398.HK+0.25%KO+0.94%CVX+0.91%0700.HK-1.26%PG+0.91%CSCO-4.29%0939.HK0.00%HD+0.72%3988.HK-1.13%BAC-3.15%1816.HK+3.45%GE-2.87%0857.HK-0.49%ORCL-8.48%UNH+2.85%1288.HK-0.45%PM-1.26%0005.HK-3.08%NVS-0.50%HSBA.L+0.29%INTC-7.97%AZN-0.60%MS-5.32%RTX-1.58%ORp+0.16%TMO-2.79%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.08%ETHUSD+71.01%USDTUSD+0.13%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.23%ZECUSDT+2.21%XMRUSDT-0.09%DOGEUSD+69.80%LINKUSD+2.45%XLMUSD-0.44%BCHUSDT-0.15%LTCUSD+68.40%UNIUSD-0.57%TONUSD+79.92%SUIUSD+1.82%HBARUSDT-0.07%TAOUSDT+2.85%AAVEUSD+1.52%ONDOUSDT+1.26%DOTUSDT+1.46%ICPUSDT+2.21%WLDUSDT+2.88%ARBUSDT+2.88%ATOMUSDT+1.90%INJUSDT+5.70%STXUSDT+4.18%PYTHUSDT+3.71%TIAUSDT+3.05%FETUSDT-0.13%SEIUSDT+0.59%JUPUSDT+2.33%GRTUSDT+0.86%OPUSDT+2.97%IOTAUSDT+2.14%POLUSDT+0.15%WIFUSDT+2.36%AXSUSDT+0.17%EOSUSDT+0.99%IMXUSDT+0.09%FARTCOINUSDT+1.61%GALAUSDT+3.50%DYDXUSDT+0.84%ORDIUSDT+2.72%NOTUSDT+1.19%RONINUSDT+1.91%
IP

Indivior Pharmaceuticals Inc (INDV)

NASDAQ • Healthcare

$28.35
-$0.6 (-2.1%)
Market closed

Last close at November 19, 2026 at 21:00 UTC

Open$29.11
Day Range$28.32 - $29.37
Avg. Volume (3M)3.9M
Market Cap$4.5B
P/E Ratio7.7
52 Week Range
$25.92$42.81

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$356M100%
Gross Profitminus cost of goods$305M86%
Operating Incomeminus R&D and overhead$181M51%
Net Incomeminus taxes and the rest$137M38%

In plain terms: out of every $100 in revenue, Indivior Pharmaceuticals Inc keeps $38 as net profit.

Fundamentals & Financials

Revenue (TTM)
$1.3B
Net Income (TTM)
$449.9M
EPS (TTM)
$3.66
ROA (TTM)
33.78%
Current Ratio
0.61

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+50.0%Q2 2026$0.96
+32.3%Q3 2026$1.15
+24.5%Q4 2026$1.32

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +24.5%

Indivior Pharmaceuticals topped consensus on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with revenue rising 13.4% year over year to about $356.0 million, driven by demand across its buprenorphine-based addiction-treatment portfolio. Adjusted EPS of $1.32 topped the $1.06 estimate (+24.5%), while revenue of $356.0 million topped the $329.4 million estimate (+8.1%). Profitability remained elevated, with gross profit of roughly $305.0 million translating to a gross margin of ~86% and operating income of about $181.0 million implying an operating margin near 51%. Net income climbed 226.2% to about $137.0 million, up from roughly $42.0 million a year ago, alongside the revenue increase from about $314.0 million in the prior-year quarter. The company generated operating cash flow of roughly $97.0 million. Consensus for the next period calls for EPS of $0.99 on revenue of $337.9 million.

View full earnings history

About Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc is a healthcare holding company that researches, produces, and distributes buprenorphine-based prescription medications designed to treat opioid dependence. Listed on the NASDAQ as INDV, it generated $1.2 billion of revenue in FY2025 from a portfolio centered on addiction-treatment therapies.

Name
Indivior Pharmaceuticals Inc
CEO
Joseph J. Ciaffoni
Industry
Healthcare
Year Founded
2014
Employees
833

Today's Snapshot

AI-generated

INDV closed 2.6% higher at 36.28, while its sector was flat.

Trading Volume

Above 10d avg 4.8M

4.8M

vs S&P 500 Today

Strong Outperformance

+6.06%

Updated: November 20, 2026 at 21:26 UTC

Technical Indicators

0 Buy2 Neutral6 Sell
INDV shows a pronounced bearish profile driven by clear downward momentum and trend strength. ADX is elevated, signaling a vigorous directional move, while MACD and momentum readings are decisively negative and the stock trades below most moving averages, including long-term averages, reflecting broad technical pressure. Average true range is relatively high as a percentage of price, indicating elevated volatility, and the pivot sits above the market, adding nearby resistance. On-balance volume is negative overall despite a buy signal flag, leaving a mixed volume picture against the dominant bearish signals. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$29.55 - $34.80
    Sell
  • RSI (14)38.14
    Neutral
  • Stochastic %K (14, 3, 3)30.00
    Neutral
  • MACD Level (12, 26)-1.72
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.